Bladder cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• HER2 47
• PD-1 18
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• MYC 0
• ERK 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

24 of 53+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  Artificial Intelligence Enhanced Detection and Monitoring of Bladder Cancer

  Vesica Corporation· San Marcos, United States· US$1,200,764 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort

  Veterans Education/Res/Assn/North/Ne· White River Junction, United States· US$594,869 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · U01

  Population modeling for bladder cancer prevention and control

  Brown University· Providence, United States· US$1,231,387 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · P50

  SPORE in Bladder Cancer

  Sloan-Kettering Inst Can Research· New York, United States· US$2,491,899 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · F31

  Investigating the effect of high methionine availability on cancer progression

  University of Southern California· Los Angeles, United States· US$50,114 awarded in fiscal year 2026· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the COMPASS that guides cancer

  Universite Libre de Bruxelles· Bruxelles, Belgium· EU contribution €2,000,000· until Sept 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetics of Bladder Cancer Evolution. (Epi-BCE)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Greece· EU contribution €197,264· until Mar 2027· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Development of Metastatic Organ-on-a-Chip for modelling the role of sex steroids in Bladder cancer metastasis to bone (DeMOBilise)

  University of Limerick· Limerick, Ireland· EU contribution €328,495· until Aug 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement (BRECISE)

  South East Technological University· Waterford, Ireland· EU contribution €13,615,935· until Dec 2029· 14 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours (IMPACT)

  Impact Biotech Ltd· Ness Tziona, Israel· EU contribution €2,498,731· until Nov 2026

10 of 192 running projects, newest first. Listed amounts together: US$123.2m + €36.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

• Terminated

  Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

  NCT04902040· M.D. Anderson Cancer Center· Updated 30 Apr 2026

  “PI requested.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Updated 12 Jan 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

  NCT04064190· MedPacto, Inc.· Updated 9 Dec 2024

  “Changing trial strategy”Registry text, quoted unchanged. Source

• Terminated

  Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

  NCT03809624· Inhibrx Biosciences, Inc· Updated 23 Oct 2024

  “Program terminated due to lack of meaningful efficacy signal.”Registry text, quoted unchanged. Source

• Withdrawn

  Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

  NCT05574504· AdventHealth· Updated 1 Aug 2024

  “PI Decision based on no enrollment”Registry text, quoted unchanged. Source

• Withdrawn

  Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

  NCT03150836· Terence Friedlander, MD· Updated 19 Oct 2017

  “Co-PI Albert Chang relocating to UCLA. IND will transfer to UCLA. UCSF will not participate.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

  NCT04579224· National Cancer Institute (NCI)· Source

• A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

  NCT04660344· Hoffmann-La Roche· Source

• Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

  NCT03711032· Merck Sharp & Dohme LLC· Source

• Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

  NCT03732677· AstraZeneca· Source

• Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

  NCT07625527· Tianjin Medical University Second Hospital· Source

• Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  NCT03924856· Merck Sharp & Dohme LLC· Source

• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

  NCT05007106· Merck Sharp & Dohme LLC· Source

• A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

  NCT05327530· EMD Serono Research & Development Institute, Inc.· Source

• Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

  NCT06439836· National Cancer Institute (NCI)· Source

• TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

  NCT07038928· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 78
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 94
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 77
• Genome-Wide Association Study 18

• Urinary Metabolomics in Bladder Cancer: A Scoping Review of Current Evidence and Translation Implications.

  Int J Mol Sci, Oct 2026

• A systematic DoE approach for optimizing urinary LC-HRMS metabolomics: enhancing reliability in bladder cancer profiling.

  Anal Bioanal Chem, Jul 2026

• Isolation of the new polyketide (-)-R-talaropinophiloic acid guided by an integrated metabolomics-dereplication approach.

  World J Microbiol Biotechnol, Jul 2026

• Evaluation of FASP for Mass Spectrometry-Based Untargeted Metabolomics Analysis of Urine Samples.

  J Proteome Res, Jun 2026

• FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.

  Commun Biol, May 2026

• Spatial multiomics profiling reveals ZFP36-mediated immunometabolic reprogramming in bladder cancer.

  Proc Natl Acad Sci U S A, Apr 2026

• Plasma metabolomic profiling identifies a metabolic signature for non-muscle-invasive bladder cancer independent of hematuria.

  Biol Direct, Apr 2026

• Serum Biomarkers in Bladder Cancer: NMR Metabolomics for Identification and Monitoring during Platinum-Based Therapy.

  Oncol Res, Mar 2026

• Urinary metabolomics identifies lactate as a biomarker for bladder cancer detection and progression.

  Mol Omics, Mar 2026

• [Analysis of urine biomarkers in urothelial carcinoma based on untargeted metabolomics].

  Se Pu, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.